CRISPR Therapeutics AG (CRSP) Profit After Tax (2015 - 2026)

CRISPR Therapeutics AG has disclosed Profit After Tax across 12 years of filings, most recently posting -$122.9 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$122.9 million, up 9.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$568.5 million (down 47.42% YoY), and the FY2025 annual result was -$581.6 million, down 58.8% from the prior year.
• Profit After Tax came in at -$122.9 million for Q1 2026 at CRISPR Therapeutics AG, up from -$130.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $89.3 million in Q4 2023 to a low of -$208.5 million in Q2 2025.
• The 5-year median for Profit After Tax is -$116.6 million (2024), against an average of -$110.3 million.
• Across the five-year window, Profit After Tax jumped 180.8% in 2023 and tumbled 250.07% in 2025, its largest moves.
• CRISPR Therapeutics AG's Profit After Tax stood at -$110.6 million in 2022, then surged by 180.8% to $89.3 million in 2023, then plunged by 141.76% to -$37.3 million in 2024, then sank by 250.07% to -$130.6 million in 2025, then gained by 5.88% to -$122.9 million in 2026.
• The last three Profit After Tax figures came in at -$122.9 million (Q1 2026), -$130.6 million (Q4 2025), and -$106.4 million (Q3 2025), per Business Quant data.